Comparing 20% Albumin Plus Ringer Lactate Versus Ringer Lactate Alone
for Fluid Therapy During Cytoreductive Surgery with Hyperthermic
Intraperitoneal Chemotherapy
Led by Assistance Publique - Hôpitaux de Paris · Updated on 2026-09-29
140
Participants Needed
8
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the use of 20% albumin combined with Ringer Lactate versus Ringer Lactate alone for fluid therapy during cytoreductive surgery CRS with hyperthermic intraperitoneal chemotherapy HIPEC. This surgery involves large fluid shifts due to resection and inflammation, and fluid management may affect postoperative outcomes. The study aims to assess whether using albumin reduces the volume of crystalloid fluids needed and improves patients prognosis after surgery.
Participants will be randomly assigned to one of two groups. The intervention group receives a bolus of 20% albumin during anesthesia induction, followed by albumin infusion adjusted to vascular filling volume, combined with Ringer Lactate. The control group receives Ringer Lactate alone based on current guidelines. Albumin infusion is stopped at surgery end. This is an open-label, randomized, parallel-group multicenter trial.
Participants are followed up to 28 days after surgery. Researchers will evaluate postoperative complications using the Comprehensive Complication Index at day 28 as the primary outcome. Secondary outcomes include mortality, fluid volumes, surgical and medical complications, organ support needs, organ failure scores, and length of stay in intensive care and hospital. Blood tests will monitor albumin levels during surgery to maintain target concentrations. The total study duration per participant includes screening before surgery and follow-up for 28 days postoperatively.
CONDITIONS
Brief Title
Efficacy of Intraoperative Use of 20% Albumin Combined With Ringer Lactate Versus Ringer Lactate During Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy
Research Team
A
Arthur Moreau, Dr
J
Jérôme Lambert, Pr
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Male and female patients aged 18 years old and older
Planned cytoreductive surgery with HIPEC for peritoneal carcinomatosis from gynecological or digestive origin
Patient volunteer for the study and provided written informed consent
Patient affiliated to the French Health Insurance
You will not qualify if you...
Adults older than 75 years
Functional status not suitable for cytoreduction with HIPEC (ECOG > 2 or Karnofsky index < 75)
Pre-existing conditions affecting albumin levels such as liver cirrhosis, nephrotic syndrome, exudative enteropathy, or malnutrition
Severe preoperative hypoalbuminemia (albumin level < 20 g/L)
History of chronic left heart failure with reduced ejection fraction (< 40%)
High risk of pulmonary complications like atelectasis or significant pleural effusions
Significant ascites causing respiratory problems
Uncontrolled diabetes (HbA1c > 8.5%)
Allergy to human albumin or Ringer Lactate
Hyperkalemia > 6.0 mmol/L
Hypercalcemia (total calcium > 2.60 mmol/L)
Chronic use of digitalis or potassium-sparing diuretics
Pregnancy or breastfeeding
Known preoperative kidney failure (GFR < 30 mL/min/1.73m2 or on dialysis)
Recent brain trauma within 6 months
Participation in another interventional human study or in exclusion period
Patient deprived of liberty
Patient under guardianship or curatorship
Your Study Journey
Screening
Duration - 2 months to 3 days before surgery
Participants are screened for eligibility to participate in the trial.
Consultation and pre-anesthetic visits
Treatment
Duration - Duration of the surgery
Participants receive fluid therapy during cytoreductive surgery with HIPEC, either 20% albumin combined with Ringer Lactate or Ringer Lactate alone according to group assignment.
Fluid administration and monitoring during surgery
Follow-up
Duration - 28 days after surgery
Participants are monitored for postoperative complications, organ function, and recovery outcomes for 28 days after surgery.
Clinical assessments and laboratory tests at regular intervals
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study on Thumbtack Needle Therapy for Improving Sleep and Recovery After Breast Cancer Surgery
in Women Aged 18 to 55 Undergoing General Anesthesia
AI Model to Predict Complications After Transcatheter Closure of Perimembranous Ventricular Septal Defect in Children
Using Multimodal Clinical Data Integration
Three-Part Study of Sofetabart Mipitecan Compared to Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer and Sofetabart Mipitecan Plus Bevacizumab Compared to Platinum Chemotherapy Plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
Study of Alert Frequency and Satisfaction With Wireless Continuous Vital Sign Monitoring in Hospital Patients and Nurses
Evaluating ARISCAT, ASA, and LAS VEGAS Risk Scores to Predict Lung Complications After Thoracic Surgery Using Single-Lung Ventilation
Using Atrial Electromechanical Changes to Predict Arrhythmias After Cardiovascular Surgery
Prospective Study of Axillary Web Syndrome Occurrence, Risk Factors, and Recovery After Breast Cancer Surgery
Using Biomarkers to Predict and Improve Outcomes After High-Risk Cardiac, Gastrointestinal, Vascular, and Lung Surgeries
Study of Blood Thickness and Brain Oxygen Levels During Elective Intracranial Craniotomy and Related Postoperative Complications
Using Cardiopulmonary Exercise Testing to Predict Complications After Coronary Artery Bypass Graft Surgery
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Efficacy of intraoperative use of 20% albumin in combination with Ringer's lactate versus Ringer's lactate during cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: protocol for a randomised controlled, open-label clinical trial (ALBUCHIP trial).